Mesoblast Limited cash flow statement MESO
In fiscal 2025, which ended Jun 30, 2025, Mesoblast Limited used $50.0 million of cash from operations, down 3.1% from the year before. It spent $680,000 on capital expenditures. Free cash flow was negative, at -$50.6 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
|---|---|---|---|---|---|---|---|---|
| Operating | ||||||||
| Depreciation and amortization |
2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Stock-based compensation |
9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Operating cash flow |
-50
-3.1%
|
-48
+23.4%
|
-63
+3.8%
|
-66
+34.7%
|
-101
-99.8%
|
-50
+12.8%
|
-58
+23.0%
|
-75
|
| Investing | ||||||||
| Capital expenditures |
1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Investing cash flow |
0
+223.7%
|
-0
+50.0%
|
-0
+16.4%
|
-0
+85.9%
|
-2
+49.7%
|
-3
-227.3%
|
-1
+13.3%
|
-1
|
| Financing | ||||||||
| Debt issued |
—
|
0
|
0
-100.0%
|
52
+10040.4%
|
—
|
1
-98.8%
|
44
+37.4%
|
32
|
| Debt repaid |
8
-21.8%
|
10
|
0
-100.0%
|
55
+10731.6%
|
—
|
1
|
—
|
—
|
| Financing cash flow |
147
+266.0%
|
40
-46.0%
|
75
+854.8%
|
-10
-109.1%
|
109
-17.2%
|
131
+83.1%
|
72
+4.4%
|
69
|
| Change in cash | ||||||||
| Effect of exchange rate |
1
+2080.0%
|
-0
+67.3%
|
-0
+69.5%
|
-1
-138.9%
|
1
-5.4%
|
1
+1065.2%
|
-0
+65.2%
|
-0
|
| Free cash flow |
-51
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Per share | ||||||||
| Free cash flow per share |
-0.04
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Ratios | ||||||||
| Free cash flow margin |
-294.42%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Capital expenditures to revenue |
3.95%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Stock-based compensation to revenue |
53.49%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MESO (Nasdaq), MEOBF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne, Victoria, Australia
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1345099
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.